An immunometabolic prodrug strategy overcomes DHODH inhibitor resistance in refractory melanoma
This dual-targeting strategy overcomes DHODH inhibitor resistance by coupling metabolic interference with innate immune activation, offering translational potential for melanoma and other treatment-resistant cancers.
Authors
- Jun-Ke Song
- Siqing Fu (ORCID: https://orcid.org/0000-0002-1933-0419)
- Renming Fan
- Gaofei Wei (ORCID: https://orcid.org/0000-0001-7180-7176)
- Ye Chen (ORCID: https://orcid.org/0000-0002-3601-0281)
- Wenhui Wang (ORCID: https://orcid.org/0000-0001-7482-692X)
- Yongrui Hai
- Junyan Zhuang
- Liang Lei (ORCID: https://orcid.org/0000-0001-5919-0898)
- Guowen Ding (ORCID: https://orcid.org/0000-0002-4736-1562)
Institutions
- Northwestern Polytechnical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1186/s13046-025-03566-6
- Citations
- 1
- Primary Topic
- Biochemical and Molecular Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81